Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV.
Saowalak TurongkaraveeNaiyana PraditsitthikornThundon NgamprasertchaiJiraphun JittikoonSurakameth MahasirimongkolChonlaphat SukasemWanvisa UdomsinprasertOlivia WuUsa ChaikledkaewPublished in: ClinicoEconomics and outcomes research : CEOR (2022)
Single and multiple-PGx testing might be cost-effective options for reducing the incidence of drug-induced serious ADRs in people living with HIV.